|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brody H: Colorectal cancer. Nature.
521:S12015. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein A, Atanackovic D and Bokemeyer C:
Current standards and new trends in the primary treatment of
colorectal cancer. Eur J Cancer. 47(Suppl 3): S312–S314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
5
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Hara MH, Hamilton SR and O'Dwyer PJ:
Molecular triage trials in colorectal cancer. Cancer J. 22:218–222.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bendell JC, Varghese AM, Hyman DM, Bauer
TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A,
et al: A First-in-human phase 1 study of LY3023414, an oral
PI3K/mTOR dual inhibitor, in patients with advanced cancer. Clin
Cancer Res. 24:3253–3262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lech G, Slotwinski R, Slodkowski M and
Krasnodebski IW: Colorectal cancer tumour markers and biomarkers:
Recent therapeutic advances. World J Gastroenterol. 22:1745–1755.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar
|
|
11
|
Dienstmann R, Rodon J, Serra V and
Tabernero J: Picking the point of inhibition: A comparative review
of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 13:1021–1031.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hart S, Novotny-Diermayr V, Goh KC,
Williams M, Tan YC, Ong LC, Cheong A, Ng BK, Amalini C, Madan B, et
al: VS-5584, a novel and highly selective PI3K/mTOR kinase
inhibitor for the treatment of cancer. Mol Cancer Ther. 12:151–161.
2013. View Article : Google Scholar :
|
|
13
|
Kolev VN, Wright QG, Vidal CM, Ring JE,
Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA and Xu Q:
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem
cells. Cancer Res. 75:446–455. 2015. View Article : Google Scholar
|
|
14
|
Kim YC and Guan KL: mTOR: A pharmacologic
target for autophagy regulation. J Clin Invest. 125:25–32. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noda T and Ohsumi Y: Tor, a
phosphatidylinositol kinase homologue, controls autophagy in yeast.
J Biol Chem. 273:3963–3966. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parzych KR and Klionsky DJ: An overview of
autophagy: Morphology, mechanism, and regulation. Antioxid Redox
Signal. 20:460–473. 2014. View Article : Google Scholar :
|
|
17
|
Janku F, McConkey DJ, Hong DS and Kurzrock
R: Autophagy as a target for anticancer therapy. Nat Rev Clin
Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Poillet-Perez L and White E: Role of tumor
and host autophagy in cancer metabolism. Genes Dev. 33:610–619.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buchser WJ, Laskow TC, Pavlik PJ, Lin HM
and Lotze MT: Cell-mediated autophagy promotes cancer cell
survival. Cancer Res. 72:2970–2979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsujimoto Y and Shimizu S: Another way to
die: Autophagic programmed cell death. Cell Death Differ. 12(Suppl
2): S1528–S1534. 2005. View Article : Google Scholar
|
|
21
|
Wang HY, Shen Y, Zhang H, Hei YY, Zhao HY,
Xin M, Lu SM and Zhang SQ: Discovery of 2-(aminopyrimidin-5-yl)-
4-(morpholin-4-yl)-6-substituted triazine as PI3K and BRAF dual
inhibitor. Future Med Chem. 10:2445–2455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Singla P, Luxami V and Paul K: Triazine as
a promising scaffold for its versatile biological behavior. Eur J
Med Chem. 102:39–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McDonald WH and Yates JR III: Shotgun
proteomics: Integrating technologies to answer biological
questions. Curr Opin Mol Ther. 5:302–309. 2003.PubMed/NCBI
|
|
24
|
Silva MN, Leite JS, Mello MF, Silva KV,
Corgozinho KB, de Souza HJ, Cunha SC and Ferreira AM: Histologic
evaluation of Ki-67 and cleaved caspase-3 expression in feline
mammary carcinoma. J Feline Med Surg. 19:440–445. 2017. View Article : Google Scholar
|
|
25
|
Pandurangan AK: Potential targets for
prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt
pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo Q and Chen D, Fan X, Fu X, Ma T and
Chen D: KRAS and PIK3CA bi-mutations predict a poor prognosis in
colorectal cancer patients: A single-site report. Transl Oncol.
13:1008742020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang
J, Qu X and Liu Y: β-Elemene-induced autophagy protects human
gastric cancer cells from undergoing apoptosis. BMC Cancer.
11:1832011. View Article : Google Scholar
|
|
31
|
Grana X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
32
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Diaz-Moralli S, Tarrado-Castellarnau M,
Miranda A and Cascante M: Targeting cell cycle regulation in cancer
therapy. Pharmacol Ther. 138:255–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng K, He Z, Kitazato K and Wang Y:
Selective autophagy regulates cell cycle in cancer therapy.
Theranostics. 9:104–125. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
White E: Deconvoluting the
context-dependent role for autophagy in cancer. Nat Rev Cancer.
12:401–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cook KL, Warri A, Soto-Pantoja DR, Clarke
PA, Cruz MI, Zwart A and Clarke R: Hydroxychloroquine inhibits
autophagy to potentiate antiestrogen responsiveness in ER+ breast
cancer. Clin Cancer Res. 20:3222–3232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee HO, Mustafa A, Hudes GR and Kruger WD:
Hydroxychloroquine destabilizes phospho-S6 in human renal carcinoma
cells. PLoS One. 10:e1314642015.
|
|
38
|
Neufeld TP: Autophagy and cell growth-the
yin and yang of nutrient responses. J Cell Sci. 125:2359–2368.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mathiassen SG, De Zio D and Cecconi F:
Autophagy and the cell cycle: A complex landscape. Front Oncol.
7:512017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
